Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nature'S Toolbox Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active prosecution is confined to 1 distinct examiner and 1 distinct art unit, implying that the current workload is not diversified across different USPTO departments. For a practitioner, the strategy for addressing the pending action can be highly specialized for the specific requirements of the 1 distinct art unit involved. This centralized approach allows for a more efficient use of resources when preparing responses.
The busiest examiner for this portfolio is SMALL, KATHERINE R, who is responsible for 1 busiest examiner pending action. Given that the total pending office actions count is 1, SMALL, KATHERINE R is the only examiner currently interacting with the company's pending applications. This creates a streamlined prosecution environment where the practitioner only needs to manage one examiner relationship. The outcome of the current pending matter rests entirely with SMALL, KATHERINE R and the standards of the 1 distinct art unit. This focus allows for a deep analysis of the examiner's past behavior to inform the current strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMALL, KATHERINE R | 1 | 68.9% | +30.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17603276 | Systems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic Proteins | SMALL, KATHERINE R | 77d overdue |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17603276 | Systems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic Proteins | SMALL, KATHERINE R | 1633 | §103 | Non-Final OA | 77d overdue | Pending | Oct 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial